VagiBIOM Lactobacillus suppository improves vaginal health index in perimenopausal women with bacterial vaginosis: a randomized control trial

Bacterial vaginosis (BV) can cause vaginal dysbiosis that may influence general vaginal health and pregnancy complications

Read More

VagiBIOM Lactobacillus suppository improves vaginal health index in perimenopausal women with bacterial vaginosis: a randomized control trial

Bacterial vaginosis (BV) can cause vaginal dysbiosis that may influence general vaginal health and pregnancy complications

Read More

Biom Pharmaceutical: Health Revolution with Microbiome Tech

In the rapidly evolving field of biotechnology, Biom Pharmaceutical is emerging as a trailblazer, pioneering advancements in microbiome technology. Founded in 2016 by the visionary scientist and entrepreneur Dr. Bobban Subhadra, alongside his business-savvy wife, Vijitha, Biom Pharmaceutical has set a new standard in the biotech industry.

Read More

Biom Pharmaceutical Launches Probiomlyte™ Electrolyte Brand Formulated with TriBiom™ Microbiome Technology

Biom Pharmaceutical, a leading name in human microbiome technology, unveils its latest innovation in hydration science: Probiomlyte™. This state-of-the-art development focuses on enhancing the natural balance of the human microbiome, highlighting the potential for overall well-being and athletic performance optimization.

Read More

Biom Pharmaceutical Launches Probiomlyte™ Electrolyte Brand Formulated with TriBiom™ Microbiome Technology

Biom Pharmaceutical, a leading name in human microbiome technology, unveils its latest innovation in hydration science: Probiomlyte™. This state-of-the-art development focuses on enhancing the natural balance of the human microbiome, highlighting the potential for overall well-being and athletic performance optimization.

Read More

Gardner Joins BIOM Pharmaceutical as Board Chairman

BIOM Pharmaceutical Corporation, an emerging biotech company focused on human microbiome technologies, is pleased to announce the appointment of Thomas E. Gardner as Chairman of the BIOM Board of Directors.

Read More

Gardner Joins BIOM Pharmaceutical as Board Chairman

BIOM Pharmaceutical Corporation, an emerging biotech company focused on human microbiome technologies, is pleased to announce the appointment of Thomas E. Gardner as Chairman of the BIOM Board of Directors.

Read More

Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.

The SARS-CoV-2 pandemic has infected over 762 million people with over 6.9 million deaths, markedly affecting human life and existence. In the US alone, over 1.12 million deaths have been reported as of March 2023. Since its first report, several SARS-CoV-2 lineages evolved in the last 24 to 30 months.

Read More

Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.

The SARS-CoV-2 pandemic has infected over 762 million people with over 6.9 million deaths, markedly affecting human life and existence. In the US alone, over 1.12 million deaths have been reported as of March 2023. Since its first report, several SARS-CoV-2 lineages evolved in the last 24 to 30 months.

Read More

“Consumers are increasingly aware of the importance of cognitive and brain health in longevity,” says Bobban Subhadra, Ph.D., CEO & Founder, Biom Probiotics. “Traditionally, it was all about brain-boosting supplements. However, with the new research on gut microbiome—your gut good flora with its genetic elements and metabolites—it is obvious that gut flora plays a key role in optimizing cognitive brain health, which we call as microbiota-gut-brain-axis. Specifically, metabolites produced by gut flora, such as short-chain fatty acids play a key role in brain health and also prevent vascular dementia.”

Biom Pharmaceutical Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants of SARS-CoV-2.

Biom Pharmaceutical announced today that the preclinical studies of antiviral preparation Bi121 showed significant antiviral activity against various strains of SARS-CoV-2 and posted the preliminary results in the bioRxiv preprint collections.

Read More

Biom Pharmaceutical Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants of SARS-CoV-2.

Biom Pharmaceutical announced today that the preclinical studies of antiviral preparation Bi121 showed significant antiviral activity against various strains of SARS-CoV-2 and posted the preliminary results in the bioRxiv preprint collections.

Read More

Microbiome Research Company Biom Pharmaceutical Launches Vee Mobile App To Maintain Optimal Feminine Health At Every Stage.

Biom Pharmaceutical, a leading microbiome research company and creator of femtech brand VagiBiom, has just launched Vee, a female-focused mobile health app that supports women’s health at each stage of the female journey.

Read More

Biom Pharmaceutical Launches VagiBiom® Feminine Probiotics Product in All Walmart Stores.

Biom Pharmaceutical VagiBiom® feminine product is now available in all Walmart stores. This novel microbiome-focused formulation was presented at Walmart’s Made in USA Open Call competition in October 2020 and got selected for launch in all Walmart stores.

Read More

Biom Pharmaceutical Launches VagiBiom® Feminine Probiotics Product in All Walmart Stores.

Biom Pharmaceutical VagiBiom® feminine product is now available in all Walmart stores. This novel microbiome-focused formulation was presented at Walmart’s Made in USA Open Call competition in October 2020 and got selected for launch in all Walmart stores.

Read More

Biom Pharmaceutical Corporation Secures Key Patents on Humanized Gut Commensal Microbiota production from USPTO for Microbiome Drug Research & Development.

Biom Pharmaceutical Corporation today announced a key landmark in their technology platform to develop drug and consumer care products that utilize modulating human microbiome

Read More

Biom Pharmaceutical Corporation Launches Biom Turmeric Bar, a Brain health Food Using its Prebiotic and Nanoemulsion Technology

Biom Pharmaceutical Corporation today announced that it launched its first gut and brain health food- Biom Turmeric bar. The products is collaborative project between Biom Pharmaceutical in Sarasota, FL and Lubdub Food Ltd, Dublin Ireland

Read More

Biom Pharmaceutical Corporation Launches Biom Turmeric Bar, a Brain health Food Using its Prebiotic and Nanoemulsion Technology

Biom Pharmaceutical Corporation today announced that it launched its first gut and brain health food- Biom Turmeric bar. The products is collaborative project between Biom Pharmaceutical in Sarasota, FL and Lubdub Food Ltd, Dublin Ireland

Read More